Chronic Myeloid Leukemia (CML) - An Update on Patient Management Strategies
SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 60 Minutes
Chronic Myeloid Leukemia (CLL) accounts for 15% of all adult leukemias. In this webcast, expert faculty will discuss the basics of CLL, differences in hematologic, cytogenetic, and molecular response levels to treatment, and improvements that have been made in disease detection through BCR-ABL gene assessment. Faculty will review the mechanism of action of tyrosine kinase inhibitors (TKI) and use in patients with relapsed disease. Participants will learn how treatment selection occurs through response assessment, how TKIs are used in CLL, and how to manage adverse events associated with TKI therapies.
This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.
1. Define what characterizes hematologic, cytogenetic, and molecular response levels based upon guideline recommendations in patients with chronic myeloid leukemia (CML)
2. Identify how a FISH panel and quantitative BCR-ABL results are used to improve the sensitivity of disease detection and inform treatment selection
3. Summarize the mechanism of action of novel oral pharmacotherapies used for upfront and refractory treatment of CML
Tajuana Bradley MS, APRN-BC
Tajuana Bradley earned her master of science – family nurse practitioner degree from Georgia State University in Atlanta, GA. She practices at Georgia Cancer Specialists, PC.
Tajuana Bradley is a member of the oncology nursing society. Ms. Bradley has presented on “Oncologic and Metabolic Emergencies" and “The Vitalness of Vital Signs.”Ms. Bradley holds several awards: the Emory University Hospital Entity Awards: Clinical Excellence Award, Oncology Services Clinical Excellence in Practice Award, and the Hematology Clinical Excellence Award.Mrs.Bradley serves as a speaker for multiple Speaker’s Bureau including Seattle Genetics, Genentech, Puma Biotechnology, Coherus Biosciences, Astra Zeneca, Merck, and Bristol Myers Squibb.
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous.
All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.
Tajuana Bradley Has no relevant disclosures
- 1.00 AMA PRA Category 1 Credit™Horizon CME designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCCThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 1.00 credit.
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Complete the post-test and score a minimum of 70%
- Submit the evaluation form.
Access to the internet is required.
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
DISCLOSURE OF UNLABELED USE:
Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.